1 TITLE PAGE

- 2 Progression / remission of Coronavirus disease 2019: Data driven recommendations for repeating SARS-
- 3 CoV-2 nucleic acid amplification tests
- 5 Kaitlyn Williams*, Reed Idriss, MD[®]; Jessica Dodge, MD*; Samuel Barasch, MD*
- 6

- 7 *Pathology and Laboratory Medicine, Danbury Hospital, Nuvance Health, Danbury, CT, USA
- 8 [®]Department of Emergency Medicine, Danbury Hospital, Nuvance Health, Danbury, CT, USA
- 9
- 10
- 11 Running Head: Recommendations for repeating SARS-CoV-2 NAA testing
- 12
- 13
- 14 Address correspondence to
- 15 Samuel Barasch, <u>Samuel.Barasch@wchn.org</u>
- 16 24 Hospital Ave. Laboratory, 2 tower
- 17 Danbury, CT 06810, USA
- 18
- 19 Word count: 1,356 words

20 ABSTRACT

- 21 **Aims**
- 22 This short study was performed to better understand the time frame associated with changes in SARS-
- 23 CoV-2 nucleic acid testing and provide recommendations for repeat testing. Recommendations were
- 24 useful as little guidance is available for repeat testing in patients being followed expectantly for changes
- 25 in disease.

26 Methods

- 27 A review of laboratory data of tests for SARS-CoV-2 nucleic acid was performed selecting patients who
- 28 had changing results. Time between changes in test results was determined to provide guidance for
- 29 repeat testing.

30 Results

- 31 The interquartile range of data for patients who had a negative to positive change in lab testing
- 32 ("progression") was 6-16 days (Median 9). The interquartile range of data for patients who had a
- positive to negative change in test results ("remission") was 9-21 days (Median 14).

34 Conclusion

- 35 Because sampling of the nares or nasopharynx can be variable, repeat testing should be performed
- 36 swiftly when symptomatic patients are negative. The data in this short study varies widely, so authors
- 37 recommend repeat testing during a period of time associated with the interquartile range or median
- 38 (see results above).

39 TITLE

40 Progression / remission of Coronavirus disease 2019: Data driven recommendations for repeating SARS-

41 CoV-2 nucleic acid amplification tests

42 INTRODUCTION

Laboratory testing for Coronavirus disease 2019 (COVID-19) has taken a prominent position in the SARS-43 CoV-2 pandemic, and nucleic acid testing has been negative in some symptomatic patients¹ and positive 44 in some patients who are asymptomatic.¹⁻³ Results which are discordant from the clinical picture are 45 46 likely due to a combination of several factors including the following: viral prodromal/incubation period^{1,4,5}, sampling discordance from different swabbing techniques and clinical abilities⁶, analytical 47 48 differences between nucleic acid detection / instruments/methods or other technical analytical complications^{6,7}, and changes in patient disease state^{1,2}. Given that analytical sensitivity is high with 49 50 nucleic acid amplification (testing methodology available early in the pandemic), clinical and biological 51 factors such as appropriate specimen collection technique, progression of disease, and regression of 52 disease can contribute to changes in values for the diagnostic nucleic amplification for SARS-CoV-2. This 53 study was undertaken to assess prevalence of laboratory data changes in SARS-CoV-2 nucleic acid 54 amplification tests, as well as time frames associated with these changes. Findings could guide testing 55 for progression or remission of disease and may contribute to biological knowledge of the disease.

56

57

58 METHODS

59 This study was reviewed by our institutional review board and received exempt determination. The 60 laboratory information system was searched for SARS-CoV-2 nucleic acid amplification tests in inpatients 61 and outpatients associated with Western Connecticut Health Network (WCHN) hospitals (Danbury, CT; 62 Norwalk, CT; New Milford, CT) through testing performed at WCHN laboratories, Connecticut

63 Department of Public Health Laboratory, and Reference Laboratories between 3/1/2020 and 64 4/19/2020. All tests were based upon presence of nucleic acid for SARS-CoV-2 in the patient 65 nasopharynx or nasal cavity. Testing laboratory, test manufacturer, and viral gene targets include the 66 following: WCHN, Abbott ID NOW™, RdRP gene; Connecticut Department of Public Health Laboratory, 67 CDC primers, N1/N2/N3 genes; Sunrise Medical Laboratories, Roche Cobas 6800/8800, ORF1 and E genes.⁸⁻¹⁰ For testing performed on site at hospitals, testing was performed according to manufacturer 68 69 specifications. Prior to 4/6/2020, all samples were collected via nasopharyngeal swabs or nasal swabs 70 and stored/transported to testing facilities in Universal Transport Media (UTM). Beginning on 4/6/2020, 71 nasal swabs without UTM were tested on Abbott ID NOW[™] analyzers. Each test was performed on a 72 separate sample. Patients with duplicate testing were identified. From the group of patients with 73 duplicate testing, a group of patients with discordant results was identified. Result verified date was 74 used to assign chronology. Number of days between discordant results was determined. Patients 75 changing from a negative to positive result were classified as "progression" while patients changing from 76 positive to negative were classified as "remission." "Progression" and "Remission" in this study refer to 77 newly appearing positive results or newly appearing negative results. In this context, the terms "progression" and "remission" imply a change of laboratory testing from negative to positive or positive 78 79 to negative. The number of days between the first positive or negative result and the first discordant 80 result was recorded as the number of days to progression or remission. Patients with same day results 81 which were discordant were recorded as 0 days between progression or remission. Figure 1 histogram 82 was created with Microsoft Excel. R 4.0.0 was used to generate scatterplots and boxplots and statistical 83 analysis.

84

85 **RESULTS**

86 Table 1: Summary of results

Number of nucleic acid amplification tests for	13,206
SARS-CoV-2 in study time period	
Number of patients tested	12,360
Number of patients with more than one test	709
Number of patients with more than one test and	591
no changes in test results	
Number of patients with a change in test result	118
Number (percentage) of patients with a change in	89 (75%) – patients with change after 1 test.
test result on 1 or 2 or tests	110 (93%) – patients with change after 2 tests.
Number of patients with Progression (change from	65
negative to positive)	
Number of patients with Regression (change from	53
positive to negative)	
Interquartile range (Median) Progression	6-16 days (9 days)
Interquartile range (Median) Regression	9-21 days (14 days)

87

88	13,206 nucleic acid amplification tests were performed and resulted in the study time period. Most
89	laboratory result dates were between 0 and 2 days following the order date with order date being
90	shortly before date and time of specimen collection. The total number of tests represented 12,360
91	patients tested. 591 patients had 688 duplicate tests which were concordant. 118 patients had 158
92	discordant duplicate SARS-CoV-2 tests. 65 patients with discordant tests were classified as
93	"progression" while 53 patients with discordant tests were classified as "regression". 3 patients had 0
94	days to progression and 1 patient had 0 days to remission. Most patients with change in laboratory
95	values had a change after 1 test (Figure1). For patients with "progression" the mean number of days
96	was 10.4 (10.9 excluding days to progression of 0) and the median was 9 (Figure 2). For patients with
97	"remission" the mean was 13.5 days (13.7 excluding days to remission of 0) and median was 14 days
98	(Figure 3).

99

100 CONCLUSION

101 Recent guidance from the Centers for Disease Control and Prevention (CDC) has been released regarding a Symptom-Based Strategy to Discontinue Isolation for Persons with COVID-19.¹¹ While the Symptom-102 103 Based strategy is appropriate for many patients, interim guidance from the CDC includes options for 104 discontinuing isolation precautions for asymptomatic test-positive patients are divided into two 105 different strategies, time-based and test-based. Isolation times for patients who have never had any 106 symptoms using the time-based strategy require 10 days since the positive test. With the test-based 107 strategy, asymptomatic carriers can be cleared from isolation with two negative tests from different samples which are more than 24 hours apart (see CDC guidance for details).¹² These recommendations 108 109 highlight both the variability in viral shedding and sampling errors possible in affecting testing results. 110 In our study, same day repeat testing was a small proportion of patients who had a change in test results 111 (0 days to progression/remission). These few patients were likely due to differences in nasopharyngeal 112 swabbing technique rather than progression from a carrier state or remission of viral production in 113 recovering patients. It is likely that some of the patients with change in lab results in the 1-2 day time 114 frame may also represent a change in test results due to nasopharyngeal swabbing technique. Repeat 115 sample collection with nasal/nasopharyngeal swab in a brief window of time is recommended to confirm a negative test.^{4,13} Little information is available regarding false positive test results which could 116 117 confound an early carrier/incubation/low symptom/convalescent carrier period in which patients lack symptoms and test positive.¹⁴ However, divergent coronavirus strains or phylogenetically similar viral 118 genomes could be involved in a repeated positive test in the absence of symptoms.^{6,13} Presence of viral 119 120 nucleic acid long after viral cultures can be recovered (i.e., culture serves as an in vitro indication of in 121 vivo organism viability) has been demonstrated and could be contributing to difficulties clearing patients 122 from isolation with a nucleic acid test-based strategy.^{15,16}

Although knowledge about viral incubation times is rapidly evolving and many studies have highly varied results, the data collected here is concordant with what is currently known about viral incubation times and post-recovery carriage times. The "progression" data collected in this study overlaps with studies which show viral incubation time of between 2 and 14 days.^{1,2,6,14,17} The "remission" data collected in this study likewise suggests a carriage time following resolution of symptoms which extends for several weeks.^{1,15,16}

129 The data presented here represents both clinical variability of sample collection as well as biological 130 behavior of SARS-CoV-2 through the window of changes in laboratory testing. However, some 131 recommendations on repeat testing can be made. For patients with high clinical suspicion and test results which are divergent from the clinical picture, swift repeat testing is recommended.^{6,13} If repeat 132 133 testing is confirmatory, and an additional repeat test is required by the clinical circumstances, repeat 134 testing after a period of time within the interquartile ranges of collected data, such as the median 135 (Figures 2,3) should be considered. Therefore, testing for progression following a repeat negative is 136 recommended at 9 days (or between 6 and 16 days) and testing for remission following a repeat positive 137 is recommended at 14 days (or between 9 and 21 days).

138 In conclusion, although some guidance can be drawn from this data for repeat testing, this study does 139 not control for sampling of the nares, testing methodology, patient disease state, or time of sampling. 140 Long term follow-up on a broader window of patients is not available at the time of writing this and 141 would give a more accurate time frame for repeat testing. Additionally, correlation with serologic 142 testing could give this data both additional validity for recommending testing times and a deeper 143 understanding of disease and immunologic dynamics. Finally, clinical details surrounding the repeat 144 testing are unavailable to the authors and would give a more thorough understanding of effective 145 utilization of testing for SARS-CoV-2.

146 REFERENCES

- 1471.Young BE, Ong SWX, Kalimuddin S, et al. Epidemiologic Features and Clinical Course of Patients148Infected With SARS-CoV-2 in Singapore. Jama. 2020.
- Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. *Euro Surveill*. 2020;25(10).
- 1523.Arons MM, Hatfield KM, Reddy SC, et al. Presymptomatic SARS-CoV-2 Infections and153Transmission in a Skilled Nursing Facility. N Engl J Med. 2020.
- 1544.Pan Y, Zhang D, Yang P, Poon LLM, Wang Q. Viral load of SARS-CoV-2 in clinical samples. Lancet155Infect Dis. 2020;20(4):411-412.
- 1565.Wei WE, Li Z, Chiew CJ, Yong SE, Toh MP, Lee VJ. Presymptomatic Transmission of SARS-CoV-2 -157Singapore, January 23-March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(14):411-415.
- 1586.Lippi G, Simundic AM, Plebani M. Potential preanalytical and analytical vulnerabilities in the159laboratory diagnosis of coronavirus disease 2019 (COVID-19). Clin Chem Lab Med. 2020.
- Study Raises Questions About False Negatives From Quick COVID-19 Test. NPR.
 <u>https://www.npr.org/sections/health-shots/2020/04/21/838794281/study-raises-questions-</u> about-false-negatives-from-quick-covid-19-test. Published 2020. Accessed.
- 163 8. Laboratories A. ID NOW COVID-19 PRODUCT INSERT. In. Rev. 3.1 ed. Abbott Diagnostics 164 Scarborough, Maine, USA2020.
- 9. Poljak M, Korva M, Knap Gasper N, et al. Clinical evaluation of the cobas SARS-CoV-2 test and a
 diagnostic platform switch during 48 hours in the midst of the COVID-19 pandemic. *J Clin Microbiol.* 2020.
- Real-time-reverse trascription PCR (rRT-PCR) assay for the detection of the current novel
 coronavirus (2019-nCoV) at the State Public Health Laboratory [press release]. Hartford, CT:
 State of Connecticut Department of Public Health, 2/27/20 2020.
- Centers for Disease Control and Prevention (CDC). Symptom-Based Strategy to Discontinue
 Isolation for Persons with COVID-19 | CDC. @CDCgov. <u>https://www.cdc.gov/coronavirus/2019-</u>
 <u>ncov/community/strategy-discontinue-isolation.html?deliveryName=USCDC_2067-DM27395</u>.
 Published 2020. Updated 2020-05-03T05:34:11Z. Accessed 05 May 2020.
- Centers for Disease Control and Prevention (CDC). Disposition of Non-Hospitalized Patients with
 COVID-19 | CDC. Centers for Disease Control and Prevention (CDC), CDC.gov.
 https://www.cdc.gov/coronavirus/2019-ncov/hcp/disposition-in-home-patients.html. Published
- 178 2020. Updated 2020-05-03T03:00:18Z. Accessed 06 May 2020.
- 179 13. World Health O. Laboratory testing for coronavirus disease (COVID-19) in suspected human 180 cases: interim guidance, 19 March 2020. Geneva: World Health Organization; 2020 2020.
- 18114.Lai CC, Liu YH, Wang CY, et al. Asymptomatic carrier state, acute respiratory disease, and182pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and183myths. J Microbiol Immunol Infect. 2020.
- 18415.Wolfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with185COVID-2019. Nature. 2020.
- 18616.Xiao AT, Tong YX, Zhang S. Profile of RT-PCR for SARS-CoV-2: a preliminary study from 56 COVID-18719 patients. Clin Infect Dis. 2020.
- 17. Christian MD, Poutanen SM, Loutfy MR, Muller MP, Low DE. Severe acute respiratory syndrome.
 Clin Infect Dis. 2004;38(10):1420-1427.

Figure 1: Repeated tests necessary for change in SARS-CoV-2 detected status






Figure 2: Days between progression (switch from negative to positive SARS-CoV-2 test results). Box shows interquartile range and median.



Patients with Negative to Positive SARS-CoV-2 NAA Results

Figure 3: Days between remission (switch from positive to negative SARS-CoV-2results). Box shows interquartile range and median.



Patients with Positive to Negative SARS-CoV-2 NAA Results